China cancer monoclonal antibodies market is estimated to grow at a CAGR of 11.6% during the forecast period. Rising new cancer incidences is the major factor driving the adoption of monoclonal antibodies therapeutics in the country. As per the World Health Organization (WHO), nearly 4.3 million new cancer incidences were reported in 2018. Lung cancer accounted for 18.1%, colorectal (12.2%), stomach (10.6%), liver (9.2%), breast (8.6%), and others (41.4%) of all new cancer incidences in 2018. This is leading to increasing demand for monoclonal antibodies for cancer therapeutics as targeted therapy. These monoclonal antibodies have a particular target on a cancer cell that intends to discover, attach to, and attack. However, some monoclonal antibodies work as immunotherapy as they support to make the response of the immune system better, which in turn, supports the body to discover and attack cancer cells more potentially. 

Visit for Global Cancer Monoclonal Antibodies Market Report at: https://www.omrglobal.com/industry-reports/cancer-monoclonal-antibodies-market

China cancer monoclonal antibodies market is segmented based on type and application. Based on type, the market is classified into naked, conjugated, and others. Based on the application, the market is classified into breast cancer, liver cancer, blood cancer, brain cancer, colorectal cancer, and others. Naked monoclonal antibodies are the most common form of antibodies used for the treatment of cancer. Most naked monoclonal antibodies bind to antigens that are normally multiple on the surface of cancer cells compared to healthy cells. BYVASDA (bevacizumab), ERBITUX (cetuximab), Trastuzumab (Herceptin), and MabThera/Rituxan (rituximab) are some naked monoclonal antibody drugs that are commonly used for cancer treatment in the country. The increasing launches of naked monoclonal antibodies biosimilars in the country are further leveraging the share of this segment. 

Some prominent players in the market include AstraZeneca plc, Pfizer Inc., Innovent Biologics, Inc., Shanghai Fosun Pharmaceutical (Group) Co., Ltd., and Amgen Inc. Product launches and partnerships and collaborations are regarded as some potential strategies implemented by the market players to increase their position in the marketplace. For instance, in October 2019, Amgen declared collaboration with BeiGene that will further widen Amgen's plans to enhance its oncology presence in China. Under the agreement, BeiGene will commercialize BLINCYTO (blinatumomab), XGEVA (denosumab), and KYPROLIS (carfilzomib) in China. Additionally, this acquisition will also support Amgen for the commercialization of its non-oncology product portfolio in China.

Research Methodology

The market study of the China cancer monoclonal antibodies market is incorporated by extensive primary and secondary research conducted by the research team at OMR.  Secondary research has been conducted to refine the available data to breakdown the market into various segments, derive total market size, market forecast, and growth rate. Different approaches have been worked on to derive the market value and market growth rate. Our team collects facts and data related to the market from different geography to provide a better regional outlook. In the report, the country-level analysis is provided by analyzing various regional players, regional tax laws and policies, consumer behavior, and macro-economic factors. Numbers extracted from Secondary research have been authenticated by conducting proper primary research. It includes tracking down key people from the industry and interviewing them to validate the data. This enables our analyst to derive the closest possible figures without any major deviations in the actual number. Our analysts try to contact as many executives, managers, key opinion leaders, and industry experts. Primary research brings authenticity in our reports.

Secondary Sources Include

• Financial reports of companies involved in the market.
• Whitepapers, research-papers, and news blogs.
• Company websites and their product catalog.

The report provides an in-depth analysis of market size, intended quality of the service preferred by consumers. The report will serve as a source for a 360-degree analysis of the market thoroughly integrating different models.

Market Segmentation

1. China Cancer Monoclonal Antibodies Market Research and Analysis by Type
2. China Cancer Monoclonal Antibodies Market Research and Analysis by Application

The Report Covers

• Comprehensive research methodology of the China cancer monoclonal antibodies market.
• This report also includes a detailed and extensive market overview with key analyst insights.
• An exhaustive analysis of macro and micro factors influencing the market guided by key recommendations.
• Analysis of regional regulations and other government policies impacting the China cancer monoclonal antibodies market.
• Insights about market determinants which are stimulating the China cancer monoclonal antibodies market.
• Detailed and extensive market segments with regional distribution of forecasted revenues.
• Extensive profiles and recent developments of market players.